# CheckMate 914 (NCT03138512)

> A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03138512
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Carcinoma, Renal Cell
- Interventions: nivolumab; ipilimumab; nivolumab placebo; ipilimumab placebo
- Enrollment: 1641
- Primary outcome: Disease-Free Survival (DFS) by BICR - Treatment Part A and B

## Commentary we found

- X threads: 33
- Podcasts: 29
- YouTube: 19

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-914-nct03138512

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03138512", "email": "<work email>"}; the inbox owner confirms by the emailed link.